Seres Therapeutics, Inc. Logo

Seres Therapeutics, Inc.

Developing live biotherapeutics from the microbiome to treat infections and immune diseases.

MCRB | US

Overview

Corporate Details

ISIN(s):
US81750R2013
LEI:
Country:
United States of America
Address:
200 SIDNEY STREET, 2139 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seres Therapeutics, Inc. is a commercial-stage biotechnology company pioneering the development of live biotherapeutics. The company focuses on modulating the gastrointestinal microbiome to treat serious diseases. Its platform creates rationally designed consortia of live bacteria intended to transform the lives of medically vulnerable patients. Seres Therapeutics' programs target the prevention of bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as the treatment of gastrointestinal-related immune diseases such as inflammatory bowel disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Seres Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Seres Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Seres Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eledon Pharmaceuticals, Inc. Logo
Develops immunomodulatory therapies to prevent organ rejection in transplant patients.
United States of America ELDN
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.